Targeting Cancer Stem Cells via AHR

Project Summary

Cancer stem cells are known to drive therapy resistance, recurrence, and the spread of tumors to distant organs, which often leads to treatment failure and death. Finding ways to target these aggressive cells is an important step toward better treatment and prevention strategies. In this project, we are exploring the possibility of targeting cancer stem cells through the AhR/CYP1A1 pathway. To our knowledge, this is a new approach, and it may open the door to more effective therapies that limit resistance and metastasis.

Figure

The endocrine therapeutic agent Tamoxifen activate AhR in breast cancer cells. T47D cells were treated with TAM 10 (µM) for 48 hours. Cells were then stained with primary antibodies against AhR (green), followed by secondary antibodies and counterstained with DAPI (red). AhR protein localization was subsequently analyzed by immunofluorescence assay.

Other Projects by Ayodele Alaiya

Renal Injury Biomarkers in Paediatric UTIs.
Plasma Proteomics in HSCT and CAR-T.
Model Systems for Cellular Senescence.
Proteomic Signatures of GVHD.